CU22545A1
(es)
*
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
EP1500329B1
(en)
*
|
1996-12-03 |
2012-03-21 |
Amgen Fremont Inc. |
Human antibodies that specifically bind human TNF alpha
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6235883B1
(en)
*
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
WO1999054357A1
(fr)
|
1998-04-14 |
1999-10-28 |
Chugai Research Institute For Molecular Medicine, Inc. |
Nouvelle proteine du type cytokine
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
AR022952A1
(es)
|
1999-03-19 |
2002-09-04 |
Smithkline Beecham Corp |
ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
|
ES2571230T3
(es)
*
|
1999-04-09 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
PL365999A1
(en)
*
|
1999-05-14 |
2005-01-24 |
Imclone Systems Incorporated |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
GEP20104998B
(en)
|
1999-06-25 |
2010-06-10 |
Genentech Inc |
Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
EP1270595B1
(en)
*
|
2000-03-03 |
2008-07-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Anti ccr4 antibody and its fragment
|
ATE316137T1
(de)
*
|
2000-05-19 |
2006-02-15 |
Scancell Ltd |
Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
|
AU2001295002B2
(en)
*
|
2000-08-09 |
2007-05-31 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
EP1777218B1
(en)
|
2000-10-20 |
2008-12-31 |
Eisai R&D Management Co., Ltd. |
Process for the preparation of 4-phenoxy quinoline derivatives
|
CU22979A1
(es)
*
|
2000-12-08 |
2004-09-09 |
Centro Inmunologia Molecular |
Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
|
NZ527283A
(en)
*
|
2001-01-29 |
2006-03-31 |
Biogen Idec Inc |
Modified antibodies and methods of use
|
AU2002327164A1
(en)
|
2001-01-29 |
2002-12-09 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
MXPA03007319A
(es)
*
|
2001-02-19 |
2003-12-04 |
Merck Patent Gmbh |
Anticuerpos contra egfr modificados, con inmunogenicidad reducida.
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
ES2334494T5
(es)
|
2001-05-11 |
2013-05-29 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específicas y usos de las mismas
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
WO2004058821A2
(en)
*
|
2002-12-27 |
2004-07-15 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
DE60237282D1
(de)
*
|
2001-06-28 |
2010-09-23 |
Domantis Ltd |
Doppelspezifischer ligand und dessen verwendung
|
US7074175B2
(en)
|
2001-07-25 |
2006-07-11 |
Erik Schroeder Handy |
Thermotherapy via targeted delivery of nanoscale magnetic particles
|
US7951061B2
(en)
*
|
2001-07-25 |
2011-05-31 |
Allan Foreman |
Devices for targeted delivery of thermotherapy, and methods related thereto
|
US6997863B2
(en)
*
|
2001-07-25 |
2006-02-14 |
Triton Biosystems, Inc. |
Thermotherapy via targeted delivery of nanoscale magnetic particles
|
US7731648B2
(en)
*
|
2001-07-25 |
2010-06-08 |
Aduro Biotech |
Magnetic nanoscale particle compositions, and therapeutic methods related thereto
|
US7241444B2
(en)
*
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
US20080193445A1
(en)
*
|
2002-01-18 |
2008-08-14 |
Liliane Goetsch |
Novel anti-IGF-IR antibodies and uses thereof
|
US20080063639A1
(en)
*
|
2002-01-18 |
2008-03-13 |
Pierre Fabre Medicament |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
|
ATE444308T1
(de)
*
|
2002-02-13 |
2009-10-15 |
Ludwig Inst Cancer Res |
Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
|
US8093357B2
(en)
*
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7332585B2
(en)
*
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
ES2263984T3
(es)
*
|
2002-06-28 |
2006-12-16 |
Domantis Limited |
Ligandos doble-especificos con una vida media serica aumentada.
|
CN102295703A
(zh)
|
2002-07-15 |
2011-12-28 |
健泰科生物技术公司 |
鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
|
EP2042517B1
(en)
|
2002-09-27 |
2012-11-14 |
Xencor, Inc. |
Optimized FC variants and methods for their generation
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
CU23097A1
(es)
*
|
2002-10-23 |
2005-11-18 |
Centro Inmunologia Molecular |
Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
|
US20060034845A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
NZ563471A
(en)
*
|
2002-11-08 |
2009-04-30 |
Ablynx Nv |
Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
|
US20060228355A1
(en)
*
|
2003-11-07 |
2006-10-12 |
Toon Laeremans |
Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
|
US20100003253A1
(en)
*
|
2002-11-08 |
2010-01-07 |
Ablynx N.V. |
Single domain antibodies directed against epidermal growth factor receptor and uses therefor
|
EP2267027A3
(en)
*
|
2002-11-08 |
2011-07-20 |
Ablynx N.V. |
Method of administering therapeutic polypeptides, and polypeptides therefor
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
ES2551682T3
(es)
*
|
2002-11-08 |
2015-11-23 |
Ablynx N.V. |
Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
US20040193752A1
(en)
*
|
2003-01-02 |
2004-09-30 |
Harpreet Singh |
System and method for providing fee-based data services
|
US20040156846A1
(en)
*
|
2003-02-06 |
2004-08-12 |
Triton Biosystems, Inc. |
Therapy via targeted delivery of nanoscale particles using L6 antibodies
|
ES2344645T3
(es)
|
2003-02-10 |
2010-09-02 |
Applied Molecular Evolution, Inc. |
Moleculas de union al abeta.
|
US8663650B2
(en)
|
2003-02-21 |
2014-03-04 |
Ac Immune Sa |
Methods and compositions comprising supramolecular constructs
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
JPWO2004080462A1
(ja)
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
c−Kitキナーゼ阻害剤
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
EP2389953A1
(en)
|
2003-06-09 |
2011-11-30 |
Samuel Waksal |
Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
EP1725249B1
(en)
|
2003-11-06 |
2014-01-08 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
CA2552658A1
(en)
*
|
2004-01-07 |
2005-07-28 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
TW200533339A
(en)
*
|
2004-03-16 |
2005-10-16 |
Bristol Myers Squibb Co |
Therapeutic synergy of anti-cancer compounds
|
AU2005224267B2
(en)
*
|
2004-03-19 |
2011-07-21 |
Imclone Llc |
Human anti-epidermal growth factor receptor antibody
|
CA2563341C
(en)
|
2004-04-08 |
2014-10-21 |
David B. Agus |
Erbb antagonists for pain therapy
|
JP5234734B2
(ja)
|
2004-06-01 |
2013-07-10 |
ジェネンテック, インコーポレイテッド |
抗体−薬物結合体および方法
|
CN103351434B
(zh)
|
2004-07-15 |
2015-09-30 |
赞科股份有限公司 |
优化的Fc变体
|
FR2873699B1
(fr)
*
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
KR20070053205A
(ko)
|
2004-09-17 |
2007-05-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
의약 조성물
|
ES2669510T3
(es)
|
2004-09-23 |
2018-05-28 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
EP2845865A1
(en)
|
2004-11-12 |
2015-03-11 |
Xencor Inc. |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
AU2005325200A1
(en)
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Fixed dosing of HER antibodies
|
CN103981190A
(zh)
|
2005-02-07 |
2014-08-13 |
罗氏格黎卡特股份公司 |
结合egfr的抗原结合分子,编码它的载体,及其应用
|
JP2008531576A
(ja)
|
2005-02-23 |
2008-08-14 |
ジェネンテック・インコーポレーテッド |
Her二量体化阻害剤を使用した、ガン患者における疾患の進行までの期間または生存の延長
|
SI1859793T1
(sl)
*
|
2005-02-28 |
2011-08-31 |
Eisai R&D Man Co Ltd |
Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
WO2006107854A2
(en)
|
2005-04-01 |
2006-10-12 |
Amgen Inc. |
Epidermal growth factor receptor gene copy number
|
CA2605781A1
(en)
*
|
2005-05-09 |
2007-04-12 |
Glycart Biotechnology Ag |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
AR053272A1
(es)
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
Determinacion de responsivos a la quimioterapia
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
AU2006283532B2
(en)
|
2005-08-19 |
2012-04-26 |
Abbvie Inc. |
Dual variable domain immunoglobin and uses thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
US8129114B2
(en)
*
|
2005-08-24 |
2012-03-06 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
CA2620594C
(en)
*
|
2005-09-01 |
2012-08-21 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition having improved disintegratability
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
WO2007052849A1
(ja)
|
2005-11-07 |
2007-05-10 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質とc-kitキナーゼ阻害物質との併用
|
US20090247576A1
(en)
*
|
2005-11-22 |
2009-10-01 |
Eisai R & D Management Co., Ltd. |
Anti-tumor agent for multiple myeloma
|
AU2006321364B2
(en)
*
|
2005-12-01 |
2011-11-10 |
Domantis Limited |
Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
|
EP1981981B1
(en)
*
|
2006-02-06 |
2011-06-29 |
Metheresis Translational Research SA |
Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
|
WO2007111964A2
(en)
*
|
2006-03-22 |
2007-10-04 |
Genimmune N.V. |
Hepatitis c virus neutralizing antibodies
|
EP2163563A1
(en)
|
2006-03-31 |
2010-03-17 |
Massachusetts Institute of Technology |
Treatment of tumors expressing mutant EGF receptors
|
CN101443009A
(zh)
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
JP5420399B2
(ja)
|
2006-05-25 |
2014-02-19 |
グラクソ グループ リミテッド |
改変型ヒト化抗インターロイキン−18抗体
|
WO2008001956A1
(fr)
*
|
2006-06-29 |
2008-01-03 |
Eisai R & D Management Co., Ltd. |
Agent thérapeutique contre la fibrose hépatique
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
US20100008910A1
(en)
|
2006-09-12 |
2010-01-14 |
John Chant |
Methods and compositions for the diagnosis and treatment of cancer
|
CU23612A1
(es)
*
|
2006-09-29 |
2010-12-08 |
Centro Inmunologia Molecular |
Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
|
US20090068110A1
(en)
*
|
2006-12-22 |
2009-03-12 |
Genentech, Inc. |
Antibodies to insulin-like growth factor receptor
|
US20100034816A1
(en)
*
|
2006-12-22 |
2010-02-11 |
Novelix Therapeutics Gmbh |
Treatment of Diabetes by at Least One Epidermal Growth Factor Receptor Specific Antibody or a Derivative Thereof
|
MX2009007987A
(es)
*
|
2007-01-25 |
2010-03-01 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
MX2009008909A
(es)
*
|
2007-03-01 |
2009-08-28 |
Symphogen As |
Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
|
NZ578824A
(en)
|
2007-03-02 |
2012-03-30 |
Genentech Inc |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
CN101688229B
(zh)
*
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
JP2010528647A
(ja)
*
|
2007-06-06 |
2010-08-26 |
ドマンティス リミテッド |
ポリペプチド、抗体可変ドメインおよびアンタゴニスト
|
US20100298156A1
(en)
|
2007-06-08 |
2010-11-25 |
Si Tuen Lee-Hoeflich |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
CN101896503B
(zh)
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
MX2010004259A
(es)
*
|
2007-10-19 |
2010-08-31 |
Pharma Mar Sa |
Tratamientos antitumorales mejorados.
|
WO2009086320A1
(en)
|
2007-12-26 |
2009-07-09 |
Xencor, Inc |
Fc variants with altered binding to fcrn
|
CN101848895B
(zh)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
WO2009063965A1
(ja)
*
|
2007-11-15 |
2009-05-22 |
Chugai Seiyaku Kabushiki Kaisha |
Anexelektoに結合するモノクローナル抗体、およびその利用
|
MX2010008187A
(es)
*
|
2008-01-29 |
2010-08-10 |
Eisai R&D Man Co Ltd |
Uso combinado de inhibidor de angiogenesis y taxano.
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
WO2009095480A1
(en)
*
|
2008-01-30 |
2009-08-06 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
KR20100126479A
(ko)
*
|
2008-03-07 |
2010-12-01 |
파르마 마르 에스.에이. |
개선된 항종양 치료법들
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
JP5646457B2
(ja)
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
KR20110016958A
(ko)
*
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
BRPI0913366A8
(pt)
*
|
2008-06-03 |
2017-07-11 |
Abbott Lab |
Imunoglobulinas de domínio variável duplo e seus usos
|
CN101602808B
(zh)
*
|
2008-06-12 |
2012-06-20 |
上海市肿瘤研究所 |
特异性结合蛋白及其使用
|
BRPI0914209A2
(pt)
*
|
2008-06-20 |
2015-11-03 |
Centro Inmunologia Molecular |
inibidor do receptor do fator de crscimento epidérmico, linha celular, composição farmacêutica, usos do inibidor e de um anticorpo e método
|
RU2011104348A
(ru)
*
|
2008-07-08 |
2012-08-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
|
MX2011001927A
(es)
*
|
2008-08-29 |
2011-04-21 |
Symphogen As |
Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
|
EP3524620A1
(en)
|
2008-10-14 |
2019-08-14 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
CA2739352C
(en)
*
|
2008-10-29 |
2021-07-13 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
EP4104821A1
(en)
|
2008-10-29 |
2022-12-21 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
CA2745271A1
(en)
*
|
2008-12-04 |
2010-06-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
JP5818688B2
(ja)
*
|
2009-01-08 |
2015-11-18 |
バイオ−ラッド ラボラトリーズ インコーポレーティッド |
核酸増幅反応の効率を改善するための方法および組成物
|
EP2210903A1
(en)
*
|
2009-01-21 |
2010-07-28 |
Monoclonal Antibodies Therapeutics |
Anti-CD160 monoclonal antibodies and uses thereof
|
KR101579771B1
(ko)
*
|
2009-03-05 |
2015-12-28 |
애브비 인코포레이티드 |
Il-17 결합 단백질
|
NZ594665A
(en)
|
2009-03-20 |
2013-08-30 |
Genentech Inc |
Bispecific anti-her antibodies
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
CN102325549A
(zh)
|
2009-03-31 |
2012-01-18 |
罗氏格黎卡特股份公司 |
用人源化抗-EGFR IgG1抗体和伊立替康治疗癌症
|
MX2011010158A
(es)
|
2009-04-07 |
2011-10-17 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-2/anti-c-met.
|
SG176074A1
(en)
|
2009-05-15 |
2011-12-29 |
Chugai Pharmaceutical Co Ltd |
Anti-axl antibody
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
UY32808A
(es)
*
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
MX2012002651A
(es)
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
ES2354922B1
(es)
|
2009-09-02 |
2012-02-07 |
Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron |
Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
WO2011047262A2
(en)
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120220594A1
(en)
|
2009-10-30 |
2012-08-30 |
Bristol-Meyers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
CN101875695B
(zh)
*
|
2009-11-11 |
2012-07-04 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗体及其编码基因与应用
|
CN101704891B
(zh)
*
|
2009-11-11 |
2011-11-09 |
中国人民解放军军事医学科学院生物工程研究所 |
一种针对表皮生长因子受体的抗体及其编码基因与应用
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
CN102712640A
(zh)
|
2010-01-12 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
三环杂环化合物、其组合物和应用方法
|
US20110189178A1
(en)
*
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
CN102892779B
(zh)
|
2010-02-18 |
2016-12-21 |
基因泰克公司 |
神经调节蛋白拮抗剂及其在治疗癌症中的用途
|
WO2011107664A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
CA2793024A1
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
RU2012145183A
(ru)
|
2010-03-29 |
2014-05-10 |
Займворкс, Инк. |
Антитела с повышенной или пониженной эффекторной функцией
|
CN101875697B
(zh)
*
|
2010-04-15 |
2014-04-30 |
北京天广实生物技术股份有限公司 |
新型抗egfr人源抗体tgm10的设计及其应用
|
RU2012148699A
(ru)
|
2010-04-16 |
2014-05-27 |
Дженентек, Инк. |
Foxo3a как прогностический биомаркер для эффективности ингибитора пути киназы pi3k/акт
|
TWI615405B
(zh)
|
2010-05-14 |
2018-02-21 |
艾伯維有限公司 |
Il-1結合蛋白
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP2586443B1
(en)
|
2010-06-25 |
2016-03-16 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
DK3029066T3
(da)
|
2010-07-29 |
2019-05-20 |
Xencor Inc |
Antistoffer med modificerede isoelektriske punkter
|
CA2807014A1
(en)
|
2010-08-03 |
2012-02-09 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
RU2013113225A
(ru)
|
2010-08-26 |
2014-10-10 |
Эббви Инк. |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
CA2808236A1
(en)
|
2010-08-31 |
2012-03-08 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
BR112013006016A2
(pt)
|
2010-09-15 |
2016-06-07 |
Hoffmann La Roche |
compostos de azabenzotiazol, composições e métodos de uso
|
BR112013010569A2
(pt)
|
2010-10-29 |
2017-07-04 |
Immunogen Inc |
moléculas de ligação de egfr não antagonísticas e imunoconjugados das mesma
|
AU2011320314B2
(en)
|
2010-10-29 |
2015-08-06 |
Immunogen, Inc. |
Novel EGFR-binding molecules and immunoconjugates thereof
|
WO2012065161A2
(en)
|
2010-11-12 |
2012-05-18 |
Scott & White Healthcare |
Antibodies to tumor endothelial marker 8
|
CA2817785A1
(en)
|
2010-11-19 |
2012-05-24 |
Toby Blench |
Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
|
AU2011361720B2
(en)
|
2010-12-21 |
2017-04-27 |
Abbvie Inc. |
IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
CN102153648B
(zh)
*
|
2011-01-27 |
2012-07-04 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗egfr人源化抗体l4-h3及其编码基因与应用
|
KR101762999B1
(ko)
|
2011-04-18 |
2017-07-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
종양 치료제
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
AU2012258637B2
(en)
|
2011-05-24 |
2017-07-20 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
WO2012166899A2
(en)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
EP2721174A1
(en)
|
2011-06-20 |
2014-04-23 |
Traslational Cancer Drugs Pharma, S.L. |
Method for predicting the clinical response to chemotherapy in a subject with cancer
|
WO2019071023A1
(en)
|
2017-10-04 |
2019-04-11 |
Yale University |
COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
|
US9464288B2
(en)
|
2011-07-11 |
2016-10-11 |
Yale University |
Compositions and methods for making selenocysteine containing polypeptides
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
WO2013024011A1
(en)
|
2011-08-12 |
2013-02-21 |
F. Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
JP2014526538A
(ja)
|
2011-09-20 |
2014-10-06 |
エフ.ホフマン−ラ ロシュ アーゲー |
イミダゾピリジン化合物、組成物及び使用方法
|
EP3611187A1
(en)
|
2011-10-10 |
2020-02-19 |
Xencor, Inc. |
A method for purifying antibodies
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
WO2013056069A1
(en)
|
2011-10-13 |
2013-04-18 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素(sclerostin)之免疫結合物
|
KR20140105765A
(ko)
|
2011-11-21 |
2014-09-02 |
이뮤노젠 아이엔씨 |
EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
|
WO2013078223A1
(en)
*
|
2011-11-23 |
2013-05-30 |
Children's Hospital & Research Center Oakland |
Anti-factor h binding protein antibodies and methods of use thereof
|
RU2019103083A
(ru)
|
2011-11-30 |
2019-03-22 |
Дженентек, Инк. |
МУТАЦИИ ErbB3 ПРИ РАКЕ
|
EP2797955A2
(en)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Dual variable domain immunoglobulins against il-13 and/or il-17
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
MX2014014356A
(es)
|
2012-05-24 |
2015-07-06 |
Fundació Inst D Investigació Biomédica De Bellvitge Idibell |
Metodo para la identificacion del origen de un cancer de origen primario desconocido.
|
AU2013270684B2
(en)
|
2012-06-08 |
2018-04-19 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
TW201402608A
(zh)
|
2012-07-12 |
2014-01-16 |
Abbvie Inc |
Il-1結合蛋白質
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
PT2766048E
(pt)
|
2012-10-12 |
2015-02-25 |
Spirogen Sarl |
Pirrolobenzodiazepinas e conjugados das mesmas
|
US10253107B2
(en)
|
2012-10-26 |
2019-04-09 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
TW202210507A
(zh)
|
2012-11-01 |
2022-03-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
EP2914626A2
(en)
|
2012-11-01 |
2015-09-09 |
Abbvie Inc. |
Stable dual variable domain immunoglobulin protein formulations
|
CN104955838B
(zh)
|
2012-11-21 |
2021-02-02 |
詹森生物科技公司 |
双特异性EGFR/c-Met抗体
|
JPWO2014098176A1
(ja)
|
2012-12-21 |
2017-01-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体のアモルファス及びその製造方法
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
DK2943511T3
(da)
|
2013-01-14 |
2019-10-21 |
Xencor Inc |
Nye heterodimeriske proteiner
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
MX2015010791A
(es)
|
2013-02-22 |
2015-11-26 |
Hoffmann La Roche |
Metodos para tratar el cancer y prevenir la resistencia a farmacos.
|
EP2964260A2
(en)
|
2013-03-06 |
2016-01-13 |
F. Hoffmann-La Roche AG |
Methods of treating and preventing cancer drug resistance
|
CA2904760A1
(en)
|
2013-03-13 |
2014-09-18 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
CN105209077B
(zh)
|
2013-03-13 |
2019-06-11 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓以及其结合物
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
CA2905070A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
WO2014144960A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
US9062108B2
(en)
|
2013-03-15 |
2015-06-23 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 and/or IL-17
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
CA3093606A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Heterodimeric proteins for induction of t cells
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
EP2968541A4
(en)
|
2013-03-15 |
2017-02-08 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
RU2658601C2
(ru)
|
2013-05-14 |
2018-06-21 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
EP3041474B1
(en)
|
2013-09-05 |
2020-03-18 |
Genentech, Inc. |
Antiproliferative compounds
|
US20150071923A1
(en)
|
2013-09-12 |
2015-03-12 |
Ge Wei |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
AR097894A1
(es)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
CA2925598A1
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
AU2014348552A1
(en)
|
2013-11-13 |
2016-06-02 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
|
BR112016013963A2
(pt)
|
2013-12-17 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
|
ES2763429T5
(es)
|
2013-12-17 |
2023-06-21 |
Hoffmann La Roche |
Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
|
NZ720736A
(en)
|
2013-12-23 |
2020-08-28 |
Bayer Pharma AG |
Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
|
MA39776A
(fr)
|
2014-03-24 |
2017-02-01 |
Hoffmann La Roche |
Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
|
KR20230022270A
(ko)
|
2014-03-28 |
2023-02-14 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
CR20160500A
(es)
|
2014-03-31 |
2016-12-14 |
Genentech Inc |
Anticuerpos anti-ox40 y métodos de uso
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
US20170158749A1
(en)
*
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
CN104152415B
(zh)
*
|
2014-08-13 |
2015-09-30 |
百泰生物药业有限公司 |
获得高产稳定表达重组抗体的骨髓瘤细胞株的方法及应用
|
MX2017001980A
(es)
|
2014-08-28 |
2017-05-04 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y metodo para su produccion.
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2016044694A1
(en)
|
2014-09-19 |
2016-03-24 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
EP3659625A1
(en)
|
2014-10-23 |
2020-06-03 |
Innate Pharma |
Treatment of cancers using anti-nkg2a agents
|
KR20170074246A
(ko)
|
2014-11-03 |
2017-06-29 |
제넨테크, 인크. |
Ox40 효능제 치료의 효능 예측 및 평가용 방법 및 바이오마커
|
CN106796235B
(zh)
|
2014-11-03 |
2021-01-29 |
豪夫迈·罗氏有限公司 |
用于检测t细胞免疫子集的测定法及其使用方法
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
WO2016077375A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
IL252480B2
(en)
|
2014-11-26 |
2023-12-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
EP3224258B1
(en)
|
2014-11-27 |
2019-08-14 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Axlに対するヒトモノクローナル抗体
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
SG11201704707PA
(en)
|
2014-12-23 |
2017-07-28 |
Genentech Inc |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
WO2016109546A2
(en)
|
2014-12-30 |
2016-07-07 |
Genentech, Inc. |
Methods and compositions for prognosis and treatment of cancers
|
EP3242875B1
(en)
|
2015-01-09 |
2022-02-23 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
JP6659703B2
(ja)
|
2015-01-09 |
2020-03-04 |
ジェネンテック, インコーポレイテッド |
ピリダジノン誘導体および癌の処置におけるそれらの使用
|
WO2016112284A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
KR20170122734A
(ko)
|
2015-02-25 |
2017-11-06 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 고미 억제 방법
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
CA2981183A1
(en)
|
2015-04-07 |
2016-10-13 |
Greg Lazar |
Antigen binding complex having agonistic activity and methods of use
|
LT3294770T
(lt)
|
2015-05-12 |
2020-12-28 |
F. Hoffmann-La Roche Ag |
Vėžio gydymo ir diagnostikos būdai
|
CA2984003A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
MX2017014740A
(es)
|
2015-06-08 |
2018-08-15 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
WO2016204193A1
(ja)
|
2015-06-16 |
2016-12-22 |
株式会社PRISM Pharma |
抗がん剤
|
AU2016280070B2
(en)
|
2015-06-17 |
2022-09-15 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
|
CN108025084A
(zh)
|
2015-06-22 |
2018-05-11 |
拜耳医药股份有限公司 |
具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc)
|
JP2018528161A
(ja)
|
2015-06-23 |
2018-09-27 |
バイエル ファーマ アクチエンゲゼルシャフト |
Ksp阻害剤との部位特異的均一複合体
|
AU2016299368B2
(en)
*
|
2015-07-27 |
2022-03-10 |
Innocimab Pte Ltd |
Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr)
|
DK3341376T3
(da)
|
2015-08-26 |
2021-03-29 |
Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio |
Kondenserede tricykliske forbindelser som proteinkinase-inhibitorer
|
US11713358B2
(en)
|
2015-08-28 |
2023-08-01 |
Amunix Pharmaceuticals, Inc. |
Chimeric polypeptide assembly and methods of making and using the same
|
EP3344806A4
(en)
|
2015-09-04 |
2019-03-20 |
OBI Pharma, Inc. |
GLYCAN NETWORKS AND METHODS OF USE
|
KR102279524B1
(ko)
|
2015-09-25 |
2021-07-20 |
제넨테크, 인크. |
항-tigit 항체 및 이의 이용 방법
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
CN105237638A
(zh)
*
|
2015-10-26 |
2016-01-13 |
无锡傲锐东源生物科技有限公司 |
抗egfr蛋白单克隆抗体杂交瘤细胞及其产生的抗egfr单克隆抗体和应用
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
US10906918B2
(en)
|
2015-12-16 |
2021-02-02 |
Genentech, Inc. |
Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
CN114395624A
(zh)
|
2016-02-29 |
2022-04-26 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
US11319383B2
(en)
|
2016-03-14 |
2022-05-03 |
Universitetet | Oslo |
Engineered immunoglobulins with altered FcRn binding
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
AU2017239637A1
(en)
|
2016-03-29 |
2018-11-15 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
MX2018012492A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para monitorear y tratar el cáncer.
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
CA3018406A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
MY200886A
(en)
|
2016-04-22 |
2024-01-22 |
Obi Pharma Inc |
Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
WO2017205538A1
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック, インコーポレイテッド |
Cbp/ep300の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
EP3469099A1
(en)
|
2016-06-08 |
2019-04-17 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
RU2022104399A
(ru)
|
2016-06-14 |
2022-05-05 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
EP3471776B1
(en)
|
2016-06-15 |
2022-05-04 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
|
US11098107B2
(en)
|
2016-06-15 |
2021-08-24 |
Sutro Biopharma, Inc. |
Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
TWI750194B
(zh)
*
|
2016-07-05 |
2021-12-21 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Egfr抗體-藥物偶聯物及其在醫藥上的應用
|
JP2019527690A
(ja)
|
2016-07-27 |
2019-10-03 |
オービーアイ ファーマ,インコーポレイテッド |
免疫原性/治療用グリカン組成物およびその使用
|
WO2018023121A1
(en)
|
2016-07-29 |
2018-02-01 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
CA3038712A1
(en)
|
2016-10-06 |
2018-04-12 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CN109862919A
(zh)
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
PE20191034A1
(es)
|
2016-10-14 |
2019-08-05 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
TWI822055B
(zh)
|
2016-11-21 |
2023-11-11 |
台灣浩鼎生技股份有限公司 |
共軛生物分子、醫藥組成物及方法
|
CA3047522A1
(en)
|
2016-12-21 |
2018-06-28 |
Bayer Pharma Aktiengesellschaft |
Specific antibody drug conjugates (adcs) having ksp inhibitors
|
EP3558388A1
(de)
|
2016-12-21 |
2019-10-30 |
Bayer Pharma Aktiengesellschaft |
Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
|
EP3589754B1
(en)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
JP2020516638A
(ja)
|
2017-04-13 |
2020-06-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを処置する方法における使用のための、インターロイキン2イムノコンジュゲート、cd40アゴニスト、および任意選択のpd−1軸結合アンタゴニスト
|
CN111132733A
(zh)
|
2017-06-30 |
2020-05-08 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
|
EP3655034A1
(en)
|
2017-07-21 |
2020-05-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CA3070297A1
(en)
|
2017-08-11 |
2019-02-14 |
Genentech, Inc. |
Anti-cd8 antibodies and uses thereof
|
AU2018329925A1
(en)
|
2017-09-08 |
2020-03-05 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
MX2020004567A
(es)
|
2017-11-06 |
2020-08-13 |
Genentech Inc |
Metodos diagnosticos y terapeuticos para el cancer.
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗pd−1配列を用いた二重特異性および単一特異性抗体
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
CU24558B1
(es)
|
2017-11-28 |
2021-12-08 |
Ct Inmunologia Molecular |
Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
JP7391027B2
(ja)
|
2018-02-26 |
2023-12-04 |
ジェネンテック, インコーポレイテッド |
抗tigit及び抗pd-l1アンタゴニスト抗体による治療のための投薬
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
US20210363590A1
(en)
|
2018-05-21 |
2021-11-25 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
SG11202010469QA
(en)
|
2018-05-23 |
2020-11-27 |
Adc Therapeutics Sa |
Molecular adjuvant
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
TW202035444A
(zh)
|
2018-06-27 |
2020-10-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
JP2021530502A
(ja)
|
2018-07-18 |
2021-11-11 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
|
US20210186880A1
(en)
|
2018-08-03 |
2021-06-24 |
Brown University |
Oral formulations with increased uptake
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
KR20210063330A
(ko)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
방광암에 대한 치료 및 진단 방법
|
EP3857230B1
(en)
|
2018-09-21 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
US20210340277A1
(en)
|
2018-10-11 |
2021-11-04 |
The Scripps Research Institute |
Antibody compounds with reactive arginine and related antibody drug conjugates
|
MX2021004348A
(es)
|
2018-10-18 |
2021-05-28 |
Genentech Inc |
Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
|
US11279698B2
(en)
|
2018-11-20 |
2022-03-22 |
Cornell University |
Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
|
JP2022515198A
(ja)
|
2018-12-19 |
2022-02-17 |
アレイ バイオファーマ インコーポレイテッド |
FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
|
JP2022515197A
(ja)
|
2018-12-19 |
2022-02-17 |
アレイ バイオファーマ インコーポレイテッド |
がんを治療するためのfgfr阻害剤としての7-((3,5-ジメトキシフェニル)アミノ)キノキサリン誘導体
|
AU2019412489A1
(en)
|
2018-12-26 |
2021-06-10 |
Innate Pharma |
Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
AU2020228383A1
(en)
|
2019-02-27 |
2021-09-23 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
|
CN113677994A
(zh)
|
2019-02-27 |
2021-11-19 |
外延轴治疗股份有限公司 |
用于评估t细胞功能和预测对疗法的应答的方法和药剂
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
EP3962947A2
(en)
|
2019-05-03 |
2022-03-09 |
F. Hoffmann-La Roche AG |
Methods of treating cancer with an anti-pd-l1 antibody
|
EP3980423A1
(en)
|
2019-06-10 |
2022-04-13 |
Sutro Biopharma, Inc. |
5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
|
JP2022536800A
(ja)
|
2019-06-17 |
2022-08-18 |
ストロ バイオファーマ インコーポレーテッド |
Toll様受容体(tlr)7/8アゴニストとしての1-(4-(アミノメチル)ベンジル)-2-ブチル-2h-ピラゾロ[3,4-c]キノリン-4-アミン誘導体および関連化合物、ならびにがん療法および診断に使用するためのその抗体薬物コンジュゲート
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
CN114616250A
(zh)
|
2019-09-04 |
2022-06-10 |
豪夫迈·罗氏有限公司 |
Cd8结合剂及其用途
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
JP2023511472A
(ja)
|
2019-10-29 |
2023-03-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二官能性化合物
|
AU2020378330A1
(en)
|
2019-11-06 |
2022-05-12 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
CA3155989A1
(en)
|
2019-11-13 |
2021-05-20 |
Jason Robert ZBIEG |
Therapeutic compounds and methods of use
|
CA3163950A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
AU2020408562A1
(en)
|
2019-12-20 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
BR112022021625A2
(pt)
|
2020-04-26 |
2022-12-06 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Imunoglobulinas modificadas
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
EP3915576A1
(en)
|
2020-05-28 |
2021-12-01 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Chimeric antigen receptors specific for p95her2 and uses thereof
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
AU2021293507A1
(en)
|
2020-06-18 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
|
CN115843335A
(zh)
|
2020-06-30 |
2023-03-24 |
国家医疗保健研究所 |
用于预测患有实体癌的患者在术前辅助治疗和根治性手术后复发和/或死亡风险的方法
|
EP4172621A1
(en)
|
2020-06-30 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
US20220119409A1
(en)
|
2020-09-23 |
2022-04-21 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
EP4223779A1
(en)
|
2020-09-30 |
2023-08-09 |
Institute Of Zoology, Chinese Academy Of Sciences |
Egfr-targeting chimeric antigen receptor
|
EP4225443A1
(en)
|
2020-10-05 |
2023-08-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
AU2022221124A1
(en)
|
2021-02-12 |
2023-08-03 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
WO2022192403A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
WO2022251296A1
(en)
|
2021-05-25 |
2022-12-01 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
AU2022294928A1
(en)
|
2021-06-14 |
2024-01-04 |
Centro De Inmunología Molecular |
Use of monoclonal antibodies against the epidermal growth factor receptor in the treatment of patients with acute hypoxaemic respiratory failure
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
WO2023018699A1
(en)
|
2021-08-10 |
2023-02-16 |
Erasca, Inc. |
Selective kras inhibitors
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
CU20210104A7
(es)
|
2021-12-21 |
2023-07-12 |
Ct Inmunologia Molecular |
Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2
|
WO2023164487A1
(en)
|
2022-02-22 |
2023-08-31 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
EP4253418A1
(en)
|
2022-03-29 |
2023-10-04 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024006272A1
(en)
|
2022-06-27 |
2024-01-04 |
Sutro Biopharma, Inc. |
β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024015229A1
(en)
|
2022-07-15 |
2024-01-18 |
Sutro Biopharma, Inc. |
Protease/enzyme cleavable linker-payloads and protein conjugates
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|